SBLA submitted to FDA for Blincyto (blinatumomab) in pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia- Amgen
Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for Blincyto (blinatumomab) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
The sBLA is based on data from the Phase I/II '205 single-arm trial, which found that treatment with Blincyto induced complete remission in a clinically meaningful number of pediatric patients with Ph- relapsed or refractory B-cell precursor ALL. Overall, the types of serious adverse events (AEs) reported in the pediatric population are consistent with the known Blincyto safety profile. The FDA approved prescribing information for Blincyto includes a boxed warning for cytokine release syndrome and neurologic toxicities.
Comment: Blincyto was granted breakthrough therapy and priority review designations by the FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. Blincyto was also recently granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-precursor ALL.
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase IIIb COSMOS clinical trial showing that treatment with Tremfya (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR)
Pfizer Inc. announced the first detailed results from the Phase II PHAROS study, which is evaluating the efficacy and safety of Braftovi (encorafenib) given in combination with Mektovi(binimetinib) to patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
Legend Biotech Corp announced that results from the Phase III CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel (ciltacabtagene autoleucel) reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have received one to three prior lines of therapy and are refractory to lenalidomide (Hazard ratio [HR]=0.26 (95% CI, 0.18–0.38); P-value [P] <0.0001)